Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is ess...

Full description

Saved in:
Bibliographic Details
Published in:Intestinal research 2022, 20(1), , pp.150-155
Main Authors: Koroku, Miki, Omori, Teppei, Kambayashi, Harutaka, Murasugi, Shun, Kuriyama, Tomoko, Ikarashi, Yuichi, Yonezawa, Maria, Arimura, Ken, Karasawa, Kazunori, Hanafusa, Norio, Kawana, Masatoshi, Tokushige, Katsutoshi
Format: Article
Language:English
Subjects:
Case Report
case reports
covid-19
granulocyte and monocyte adsorptive apheresis
ulcerative colitis
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
ISSN:1598-9100
2288-1956
DOI:10.5217/ir.2020.00148